Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Yaqrit logo — The Liver Disease Company

Yaqrit

The Liver Disease Company

Founded 2014 United Kingdom London, United Kingdom 14 employees Convertible Note Total: $15.70M Biotechnology, Health Care +3

General Information

Company Name Yaqrit
Founded Year 2014
Location United Kingdom London, United Kingdom
Employees 14
Industries Biotechnology, Health Care, Life Sciences +2
Funding Stage Convertible Note
Business Model B2B, B2C, B2D
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Yaqrit. To contact Yaqrit, visit yaqrit.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Yaqrit compare?

A PDF of Yaqrit and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Yaqrit soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Yaqrit

Yaqrit Limited, known as "The Liver Disease Company", is at the forefront of developing innovative treatments for liver disease, aiming to revolutionize patient care globally. Founded in 2014, this United Kingdom-based biotechnology startup is a spinout from University College London (UCL), one of the world’s top universities.

The company’s foundation is strongly rooted in over 20 years of extensive research led by Professor Rajiv Jalan and his team at the Royal Free Hospital campus. Yaqrit operates within key industries such as Biotechnology, Health Care, Life Sciences, Medical Devices, and Pharmaceutical, showcasing a diversified approach to tackling liver disease.

Its last financial injection was a Convertible Note investment on 03 September 2020 by Trend Investment Group. With its strategic focus on cutting-edge liver disease solutions and robust academic backing, Yaqrit presents a compelling investment opportunity within the life sciences sector.

Business keywords: Liver Disease Treatments, Chronic Liver Disease, Medical Spinout, University Collaboration, Biomedical Research, Life Sciences, Professor Rajiv Jalan, Translational Medicine, Innovative Therapies, Healthcare Innovation, Treatment Development, Liver Cirrhosis Solutions, Advanced Biomedical Solutions

Services & Products

Research and development of treatments for advanced liver disease
Clinical trials for new liver disease therapies
Development of microbiome-based therapeutics

Target Customers

Patients with advanced liver disease Healthcare professionals Medical researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note Undisclosed 1
Trend Investment Group
03 Sep 2020
Private Equity Round Undisclosed 1
Riveria Investment Group
09 Jul 2020
Angel Round £1.40M -
01 Dec 2016
Grant €6.40M 1
Horizon 2020
01 Dec 2016
Angel Round £2.00M 1
UCLB
UCLB
17 Dec 2015
Grant €5.90M 1
Horizon 2020
14 Apr 2015

Yaqrit Alternatives & Competitors

View All Alternatives
Yaqrit vs
HepaRegeniX GmbH
HepaRegeniX GmbH Germany

Unlocking liver regeneration - delivering recovery

15 employees
Biotechnology, Health Care
Yaqrit vs
Berlin Institute of Health in der Charité
Berlin Institute of Health in der Charité Germany

Aus Forschung wird Gesundheit

561 employees
Biotechnology, Health Care
Yaqrit vs
FimmCyte
FimmCyte Switzerland

First disease modifying treatment for Endometriosis.

Seed
7 employees
Biotechnology, Health Care
Also compare with: Yaqrit vs ABK Biomedical Inc. ABK Biomedical Inc. View all alternatives

FAQ About Yaqrit

The Liver Disease Company
Yaqrit was founded in 2014.
Yaqrit is headquartered in London, United Kingdom.
Yaqrit operates in Biotechnology, Health Care, Life Sciences, Medical Devices and Pharmaceutical. Its work centres on Liver Disease Treatments, Chronic Liver Disease, Medical Spinout and University Collaboration. Its customers include Patients with advanced liver disease, Healthcare professionals and Medical researchers.
Yaqrit has a B2B, B2C and B2D business model. Its revenue comes from Licensing, Product Sales and Performance Based.
Yaqrit has approximately 14 employees.
Yaqrit has completed 6 funding rounds, raising a total of $15.70M. The latest funding stage is Convertible Note.
Yaqrit offers: Research and development of treatments for advanced liver disease, Clinical trials for new liver disease therapies, Development of microbiome-based therapeutics.
Top alternatives and competitors to Yaqrit include HepaRegeniX GmbH, Berlin Institute of Health in der Charité, FimmCyte, Adendra Therapeutics, ABK Biomedical Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Yaqrit and HepaRegeniX GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Yaqrit, https://bouncewatch.com/company/yaqrit, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes